{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T10:39:48Z","timestamp":1791283188233,"version":"4.1.0"},"reference-count":30,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"Supplement 2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2008,9,1]]},"DOI":"10.1097\/qai.0b013e318186519c","type":"journal-article","created":{"date-parts":[[2008,8,25]],"date-time":"2008-08-25T07:08:26Z","timestamp":1219648106000},"page":"S79-S85","source":"Crossref","is-referenced-by-count":96,"title":["HIV and Antiretroviral Therapy: Lipid Abnormalities and Associated Cardiovascular Risk in HIV-Infected Patients"],"prefix":"10.1097","volume":"49","author":[{"given":"Donald P","family":"Kotler","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-3-20210131","first-page":"1045","article-title":"Lipids, lipoproteins, triglyceride clearance, and cytokines in human immunodeficiency virus infection and the acquired immunodeficiency syndrome.","volume":"74","author":"Grunfeld","year":"1992","journal-title":"J Clin Endocrinol Metab"},{"key":"R2-3-20210131","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/0002-9343(91)80154-E","article-title":"Circulating interferon- levels and hypertriglyceridemia in the acquired immunodeficiency syndrome.","volume":"90","author":"Grunfeld","year":"1991","journal-title":"Am J Med"},{"key":"R3-3-20210131","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1016\/0140-6736(92)91058-G","article-title":"Endogenous interferon and triglyceride concentrations to assess response to zidovudine in AIDS and advanced AIDS-related complex.","volume":"339","author":"Mildvan","year":"1992","journal-title":"Lancet"},{"key":"R4-3-20210131","doi-asserted-by":"crossref","first-page":"2978","DOI":"10.1001\/jama.289.22.2978","article-title":"Impact of HIV infection and HAART on serum lipids in men.","volume":"289","author":"Riddler","year":"2003","journal-title":"JAMA"},{"key":"R5-3-20210131","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1038\/nm1201-1327","article-title":"HIV protease inhibitors protect apolipoprotein B from degradation by the proteasome: a potential mechanism for protease inhibitor-induced hyperlipidemia.","volume":"7","author":"Liang","year":"2001","journal-title":"Nat Med"},{"issue":"Suppl 2","key":"R6-3-20210131","first-page":"L5","article-title":"Nevirapine increases high density lipoprotein-cholesterol by stimulation of apoprotein A1 synthesis.","volume":"12","author":"Sankatsing","year":"2007","journal-title":"Antiviral Ther"},{"key":"R13-3-20210131","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1016\/S0140-6736(06)69155-1","article-title":"The KLEAN study of fosamprenavir-ritonavir versus lopinavir-ritonavir, each in combination with abacavir-lamivudine, for initial treatment of HIV infection over 48 weeks: a randomised non-inferiority trial.","volume":"368","author":"Eron","year":"2006","journal-title":"Lancet"},{"issue":"Suppl 2","key":"R17-3-20210131","first-page":"L8","article-title":"Effects of tipranavir\/r (500\/200 or 500\/100 mg bid) in comparison with lopinavir\/r (400\/100 mg bid) on changes in body composition and metabolic parameters in ARV-naive patients over 48 weeks.","author":"Carr","year":"2007","journal-title":"Antiviral Ther"},{"key":"R25-3-20210131","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1001\/jama.292.2.191","article-title":"Efficacy and safety of tenofovir DF vs stavudine in combination therapy in antiretroviral-naive patients: a 3-year randomized trial.","volume":"292","author":"Gallant","year":"2004","journal-title":"JAMA"},{"key":"R26-3-20210131","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1097\/QAI.0b013e31815acab8","article-title":"Tenofovir disoproxil fumarate, emtricitabine, and efavirenz compared with zidovudine\/lamivudine and efavirenz in treatment-naive patients: 144 week analysis.","volume":"47","author":"Arribas","year":"2008","journal-title":"J Acquir Immune Defic Syndr"},{"key":"R27-3-20210131","first-page":"62","article-title":"The impact of abacavir on lipids and lipodystrophy.","volume":"15","author":"Moyle","year":"2005","journal-title":"AIDS Read"},{"key":"R29-3-20210131","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1097\/QAI.0b013e31802bf122","article-title":"Less lipoatrophy and better lipid profile with abacavir as compared to stavudine: 96-week results of a randomized study.","volume":"44","author":"Podzamczer","year":"2007","journal-title":"J Acquir Immune Defic Syndr"},{"issue":"Suppl 2","key":"R30-3-20210131","first-page":"L57","article-title":"Lack of evidence of metabolic abnormalities and mitochondrial toxicity with enfuvirtide: a double-blind, placebo-controlled, cross-over study with random sequence assignation in healthy adult volunteers.","volume":"12","author":"Villarroel","year":"2007","journal-title":"Antiviral Ther"},{"key":"R33-3-20210131","doi-asserted-by":"crossref","first-page":"1328","DOI":"10.1016\/S0140-6736(05)79053-X","article-title":"Severe premature coronary artery disease with protease inhibitors.","volume":"351","author":"Henry","year":"1998","journal-title":"Lancet"},{"key":"R34-3-20210131","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1097\/00126334-200208150-00002","article-title":"Do protease inhibitors increase the risk for coronary heart disease in patients with HIV-1 infection?","volume":"30","author":"Klein","year":"2002","journal-title":"J Acquir Immune Defic Syndr"},{"key":"R35-3-20210131","doi-asserted-by":"crossref","first-page":"2479","DOI":"10.1097\/00002030-200311210-00010","article-title":"Increased risk of myocardial infarction with duration of protease inhibitor therapy in HIV-infected men.","volume":"17","author":"Mary-Krause","year":"2003","journal-title":"AIDS"},{"key":"R36-3-20210131","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1097\/00126334-200308010-00012","article-title":"Coronary heart disease in HIV-infected individuals.","volume":"33","author":"Currier","year":"2003","journal-title":"J Acquir Immune Defic Syndr"},{"key":"R42-3-20210131","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1056\/NEJMoa022048","article-title":"Cardiovascular and cerebrovascular events in patients treated for human immunodeficiency virus infection.","volume":"348","author":"Bozzette","year":"2003","journal-title":"N Engl J Med"},{"key":"R43-3-20210131","first-page":"1993","article-title":"Weber R, et al, and the Data Collection on Adverse Events of Anti-HIV Drugs (DAD) Study Group. Combination antiretroviral therapy and the risk of myocardial infarction.","volume":"349","author":"Friis-Moller","year":"2003","journal-title":"N Engl J Med"},{"key":"R44-3-20210131","doi-asserted-by":"crossref","first-page":"1723","DOI":"10.1056\/NEJMoa062744","article-title":"Class of antiretroviral drugs and the risk of myocardial infarction.","volume":"356","author":"DAD Study","year":"2007","journal-title":"N Engl J Med"},{"key":"R46-3-20210131","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1161\/01.CIR.104.3.257","article-title":"Use of human immunodeficiency virus-1 protease inhibitors is associated with atherogenic lipoprotein changes and endothelial dysfunction.","volume":"104","author":"Stein","year":"2001","journal-title":"Circulation"},{"key":"R52-3-20210131","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1111\/j.1468-1293.2006.00362.x","article-title":"The use of the Framingham equation to predict myocardial infarctions in HIV-infected patients: comparison with observed events in the D:A:D Study.","volume":"7","author":"Law","year":"2006","journal-title":"HIV Med"},{"key":"R53-3-20210131","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1097\/01.aids.0000174451.78497.8f","article-title":"Substitution of nevirapine or efavirenz for protease inhibitor versus lipid-lowering therapy for the management of dyslipidemia.","volume":"19","author":"Calza","year":"2005","journal-title":"AIDS"},{"key":"R54-3-20210131","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1056\/NEJMoa021589","article-title":"Substitution of nevirapine, efavirenz, or abacavir for protease inhibitors in patients with human immunodeficiency virus infection.","volume":"349","author":"Martinez","year":"2003","journal-title":"N Engl J Med"},{"key":"R55-3-20210131","doi-asserted-by":"crossref","first-page":"1484","DOI":"10.1086\/517497","article-title":"Efficacy and safety of atazanavir-based highly active antiretroviral therapy in patients with virologic suppression switched from a stable, boosted or unboosted protease inhibitor treatment regimen: the SWAN Study (AI424-097) 48-week results.","volume":"44","author":"Gatell","year":"2007","journal-title":"Clin Infect Dis"},{"key":"R58-3-20210131","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.1097\/00002030-200108170-00007","article-title":"Dietary advice with or without pravastatin for the management of hypercholesterolaemia associated with protease inhibitor therapy.","volume":"15","author":"Moyle","year":"2001","journal-title":"AIDS"},{"key":"R59-3-20210131","first-page":"2486","article-title":"Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive summary of the third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel IE).","volume":"255","year":"2001","journal-title":"JAMA"},{"key":"R60-3-20210131","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1016\/j.atherosclerosis.2006.11.037","article-title":"Comparative effects on lipid levels of combination therapy with a statin and extended-release niacin or ezetimibe versus a statin alone (the COMPELL study).","volume":"192","author":"McKenney","year":"2007","journal-title":"Atherosclerosis"},{"key":"R61-3-20210131","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1586\/14779072.6.3.391","article-title":"Prescription omega-3 fatty acids and their lipid effects: physiologic mechanisms of action and clinical implications.","volume":"6","author":"Bays","year":"2008","journal-title":"Expert Rev Cardiovasc Ther"},{"key":"R62-3-20210131","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1056\/NEJMoa0800742","article-title":"Stroes ES, et al, and the ENHANCE Investigators. Simvastatin with or without ezetimibe in familial hypercholesterolemia.","volume":"358","author":"Kastelein","year":"2008","journal-title":"N Engl J Med"}],"container-title":["JAIDS Journal of Acquired Immune Deficiency Syndromes"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/journals.lww.com\/00126334-200809012-00003","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,4,10]],"date-time":"2021-04-10T07:23:12Z","timestamp":1618039392000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00126334-200809012-00003"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,9,1]]},"references-count":30,"journal-issue":{"issue":"Supplement 2","published-print":{"date-parts":[[2008]]}},"URL":"https:\/\/doi.org\/10.1097\/qai.0b013e318186519c","relation":{},"ISSN":["1525-4135"],"issn-type":[{"value":"1525-4135","type":"print"}],"subject":[],"published":{"date-parts":[[2008,9,1]]}}}